Does Rallies show Form 4 insider transactions for TMDX?

Yes. Rallies tracks TMDX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TMDX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TMDX. It does not provide personalized investment advice.

TMDX (TransMedics) Stock Analysis - Insider Trades

TransMedics (TMDX) is a publicly traded Healthcare sector company. As of May 21, 2026, TMDX trades at $68.09 with a market cap of $2.36B and a P/E ratio of 13.62. TMDX moved +2.92% today. Year to date, TMDX is -46.15%; over the trailing twelve months it is -45.47%. Its 52-week range spans $55.00 to $160.80. Analyst consensus is buy with an average price target of $130.80. Rallies surfaces TMDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TMDX stock inside the company?

Recent TMDX insider activity includes Lovell Stephanie sold 1.19K, Weill David sold 3.57K, Hernandez Gerardo sold 1.32K, Hernandez Gerardo sold 5.91K, and Hernandez Gerardo sold 375. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TMDX Key Metrics

Key financial metrics for TMDX
Metric	Value
Price	$68.09
Market Cap	$2.36B
P/E Ratio	13.62
EPS	$5.05
Dividend Yield	0.00%
52-Week High	$160.80
52-Week Low	$55.00
Volume	2.78K
Avg Volume	0
Revenue (TTM)	$635.89M
Net Income	$171.92M
Gross Margin	59.09%

Recent TMDX Insider Trades

Lovell Stephanie sold 1.19K (~$178.50K) on Mar 4, 2026.
Weill David sold 3.57K (~$524.29K) on Mar 4, 2026.
Hernandez Gerardo sold 1.32K (~$194.91K) on Mar 4, 2026.
Hernandez Gerardo sold 5.91K (~$870.31K) on Mar 4, 2026.
Hernandez Gerardo sold 375 (~$52.17K) on Mar 2, 2026.

Latest TMDX News

TransMedics Reports Double-Digit Q1 Revenue Growth, Confirms Full-Year Guidance — May 8, 2026
TransMedics Q1 Revenue Climbs 21% to $173.9M, Unveils CHOPS, European Push — May 5, 2026
TransMedics Invests in PAD Aviation to Build European Organ Transplant Air Logistics Network — Apr 29, 2026
TransMedics Unveils CHOPS to Back OCS ENHANCE Heart and DENOVO Lung Trials — Apr 23, 2026
TransMedics Reports Jump in Q4 Profit, Shares Climb — Feb 25, 2026

TMDX Analyst Consensus

11 analysts cover TMDX: 0 strong buy, 7 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $130.80.

Common questions about TMDX

Who is trading TMDX stock inside the company?: Recent TMDX insider activity includes Lovell Stephanie sold 1.19K, Weill David sold 3.57K, Hernandez Gerardo sold 1.32K, Hernandez Gerardo sold 5.91K, and Hernandez Gerardo sold 375. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TMDX?: Yes. Rallies tracks TMDX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TMDX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TMDX. It does not provide personalized investment advice.